Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. (Q53112763)
Jump to navigation
Jump to search
scientific article published in April 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. |
scientific article published in April 2013 |
Statements
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. (English)
Wei Bai
Yong Ji Wang
Yan Zhao
Zhan Xin Yin
Chuang Ye He
Rui Jun Li
Kai Chun Wu
Jie Lai Xia
Dai Ming Fan
Guo Hong Han
1 April 2013
14
4
181-190
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference